N-MER, INC.Option Agreement • April 1st, 2002 • Hyseq Inc • In vitro & in vivo diagnostic substances • California
Contract Type FiledApril 1st, 2002 Company Industry Jurisdiction
BY AND AMONG HYSEQ, INC.,Agreement and Plan of Merger • November 12th, 2002 • Hyseq Inc • In vitro & in vivo diagnostic substances • Delaware
Contract Type FiledNovember 12th, 2002 Company Industry Jurisdiction
EXHIBIT 4.9 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this "Agreement") is made and entered into as of November 13, 2001, among Hyseq, Inc., a Nevada corporation (the "Company"), and Affymetrix, Inc. a Delaware corporation (the...Registration Rights Agreement • April 1st, 2002 • Hyseq Inc • In vitro & in vivo diagnostic substances • New York
Contract Type FiledApril 1st, 2002 Company Industry Jurisdiction
Hyseq, Inc. andRights Agreement • July 31st, 1998 • Hyseq Inc • In vitro & in vivo diagnostic substances • Nevada
Contract Type FiledJuly 31st, 1998 Company Industry Jurisdiction
HYSEQ, INC.Warrant Agreement • June 12th, 1997 • Hyseq Inc • New York
Contract Type FiledJune 12th, 1997 Company Jurisdiction
between HYSEQ, INC. and AFFYMETRIX, INC.Settlement Agreement • July 22nd, 2002 • Hyseq Inc • In vitro & in vivo diagnostic substances • California
Contract Type FiledJuly 22nd, 2002 Company Industry Jurisdiction
EXHIBIT 10.7 HYSEQ, INC.Stock Purchase Agreement • June 12th, 1997 • Hyseq Inc • California
Contract Type FiledJune 12th, 1997 Company Jurisdiction
HYSEQ, INC. WARRANTHyseq Inc • June 14th, 2002 • In vitro & in vivo diagnostic substances
Company FiledJune 14th, 2002 Industry
HYSEQ, INC.Registration Rights Agreement • June 12th, 1997 • Hyseq Inc • Illinois
Contract Type FiledJune 12th, 1997 Company Jurisdiction
EXHIBIT 4.7 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this "Agreement") is made and entered into as of April 5, 2002, by and among Hyseq, Inc., a Nevada corporation (the "Company"), and the investors signatory hereto (each a...Registration Rights Agreement • June 14th, 2002 • Hyseq Inc • In vitro & in vivo diagnostic substances • New York
Contract Type FiledJune 14th, 2002 Company Industry Jurisdiction
HYSEQ, INC.Underwriting Agreement • July 17th, 1997 • Hyseq Inc • In vitro & in vivo diagnostic substances • New York
Contract Type FiledJuly 17th, 1997 Company Industry Jurisdiction
EXHIBIT 4.6 RIGHTS AGREEMENT AMENDMENT This Amendment, dated as of November 9, 2002, to the Rights Agreement, dated as of June 5, 1998 (the "Rights Agreement"), is between Hyseq, Inc., a Nevada corporation (the "Company"), and U.S. Stock Transfer...Rights Agreement • November 27th, 2002 • Hyseq Inc • In vitro & in vivo diagnostic substances • Delaware
Contract Type FiledNovember 27th, 2002 Company Industry Jurisdiction
ARCA BIOPHARMA, INC., Issuer AND [TRUSTEE], Trustee FORM OF INDENTURE Dated as of [—], 20 Subordinated Debt SecuritiesIndenture • March 9th, 2011 • ARCA Biopharma, Inc. • In vitro & in vivo diagnostic substances • New York
Contract Type FiledMarch 9th, 2011 Company Industry JurisdictionWHEREAS, for its lawful corporate purposes, the Company has duly authorized the execution and delivery of this Indenture to provide for the issuance of subordinated debt securities (hereinafter referred to as the “Securities”), in an unlimited aggregate principal amount to be issued from time to time in one or more series as in this Indenture provided, as registered Securities without coupons, to be authenticated by the certificate of the Trustee;
ARTICLE I. DEFINITIONSSecurities Purchase Agreement • June 14th, 2002 • Hyseq Inc • In vitro & in vivo diagnostic substances • New York
Contract Type FiledJune 14th, 2002 Company Industry Jurisdiction
ARCA BIOPHARMA, INC. AND , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF __________Warrant Agreement • May 7th, 2020 • ARCA Biopharma, Inc. • In vitro & in vivo diagnostic substances • New York
Contract Type FiledMay 7th, 2020 Company Industry JurisdictionTHIS COMMON STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [•], between ARCA BIOPHARMA, INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized and existing under the laws of [•] and having a corporate trust office in [•], as warrant agent (the “Warrant Agent”).
ARCA biopharma, Inc.ARCA Biopharma, Inc. • July 22nd, 2020 • In vitro & in vivo diagnostic substances • New York
Company FiledJuly 22nd, 2020 Industry JurisdictionARCA biopharma, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with JonesTrading Institutional Services LLC (the “Agent”), as follows:
ARTICLE I DEFINITIONSSecurities Purchase Agreement • September 25th, 2001 • Hyseq Inc • In vitro & in vivo diagnostic substances • New York
Contract Type FiledSeptember 25th, 2001 Company Industry Jurisdiction
ARCA BIOPHARMA, INC. AND , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF [ ], 20Common Stock Warrant Agreement • April 25th, 2017 • ARCA Biopharma, Inc. • In vitro & in vivo diagnostic substances • New York
Contract Type FiledApril 25th, 2017 Company Industry JurisdictionThis COMMON STOCK WARRANT AGREEMENT (this “Agreement”), dated as of between ARCA BIOPHARMA, INC., a Delaware corporation (the “Company”), and , a [corporation] [national banking association] organized and existing under the laws of and having a corporate trust office in , as warrant agent (the “Warrant Agent”).
ARCA BIOPHARMA, INC. AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OFWarrant Agreement • May 7th, 2020 • ARCA Biopharma, Inc. • In vitro & in vivo diagnostic substances • New York
Contract Type FiledMay 7th, 2020 Company Industry JurisdictionTHIS DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of [•], between ARCA BIOPHARMA, INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized and existing under the laws of [•] and having a corporate trust office in [•], as warrant agent (the “Warrant Agent”).
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • January 23rd, 2013 • ARCA Biopharma, Inc. • In vitro & in vivo diagnostic substances • New York
Contract Type FiledJanuary 23rd, 2013 Company Industry JurisdictionThis REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of January , 2013, is by and among ARCA biopharma, Inc., a Delaware corporation (the “Company”), and the undersigned buyer ( “Buyer”).
HYSEQ INC. HYSEQ, INC. STOCK OPTION AGREEMENT ----------------------Hyseq Inc • May 20th, 1998 • In vitro & in vivo diagnostic substances • California
Company FiledMay 20th, 1998 Industry Jurisdiction
EXHIBIT 10.29 WARRANT PURCHASE AGREEMENT This Warrant Purchase Agreement (the "Agreement") is made as of January 8, 2002 by and between Hyseq, Inc., a Nevada corporation (the "Company"), and Amgen Inc., a Delaware corporation ("Purchaser"). The...Warrant Purchase Agreement • May 15th, 2002 • Hyseq Inc • In vitro & in vivo diagnostic substances • California
Contract Type FiledMay 15th, 2002 Company Industry Jurisdiction
ARCA BIOPHARMA, INC. AND , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF [ ], 20Preferred Stock Warrant Agreement • April 25th, 2017 • ARCA Biopharma, Inc. • In vitro & in vivo diagnostic substances • New York
Contract Type FiledApril 25th, 2017 Company Industry JurisdictionThis PREFERRED STOCK WARRANT AGREEMENT (this “Agreement”), dated as of between ARCA BIOPHARMA, INC., a Delaware corporation (the “Company”), and , a [corporation] [national banking association] organized and existing under the laws of and having a corporate trust office in , as warrant agent (the “Warrant Agent”).
Exhibit 99.1 VOTING AGREEMENT VOTING AGREEMENT (the "Agreement"), dated as of November 9, 2002, between the undersigned stockholder ("Stockholder") of Hyseq, Inc., a Nevada corporation ("Parent"), and Variagenics, Inc., a Delaware corporation (the...Voting Agreement • November 12th, 2002 • Hyseq Inc • In vitro & in vivo diagnostic substances • Delaware
Contract Type FiledNovember 12th, 2002 Company Industry Jurisdiction
ARTICLE 1. DEFINITIONS -----------Patent License Agreement • August 7th, 1997 • Hyseq Inc • In vitro & in vivo diagnostic substances • Illinois
Contract Type FiledAugust 7th, 1997 Company Industry Jurisdiction
NUVELO, INC. INDENTURENuvelo Inc • July 8th, 2003 • In vitro & in vivo diagnostic substances • New York
Company FiledJuly 8th, 2003 Industry Jurisdiction
ARCA BIOPHARMA, INC. and , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF [ ], 20Debt Securities Warrant Agreement • April 25th, 2017 • ARCA Biopharma, Inc. • In vitro & in vivo diagnostic substances • New York
Contract Type FiledApril 25th, 2017 Company Industry JurisdictionThis DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of between ARCA BIOPHARMA, INC., a Delaware corporation (the “Company”), and , a [corporation] [national banking association] organized and existing under the laws of and having a corporate trust office in , as warrant agent (the “Warrant Agent”).
EXHIBIT 10.3(a) EMPLOYMENT AGREEMENT -------------------- THIS EMPLOYMENT AGREEMENT ("Agreement"), made and entered into as of the 1st day of August, 1994, by and between HYSEQ, INC., a Nevada corporation (the "Corporation"), and DR. RADOJE T. DRMANAC...Employment Agreement • June 12th, 1997 • Hyseq Inc • Illinois
Contract Type FiledJune 12th, 1997 Company Jurisdiction
UNDERWRITING AGREEMENT DATED FEBRUARY 1, 2005 NUVELO, INC. 8,500,000 Shares Common Stock ($0.001 par value per Share) UNDERWRITING AGREEMENTUnderwriting Agreement • February 2nd, 2005 • Nuvelo Inc • In vitro & in vivo diagnostic substances • New York
Contract Type FiledFebruary 2nd, 2005 Company Industry JurisdictionNuvelo, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the underwriters named in Schedule A annexed hereto (the “Underwriters”), for whom you are acting as representatives, an aggregate of 8,500,000 shares (the “Firm Shares”) of common stock, $0.001 par value per share (the “Common Stock”), of the Company. In addition, solely for the purpose of covering over-allotments, the Company proposes to grant to the Underwriters the option to purchase from the Company up to an additional 1,275,000 shares of Common Stock (the “Additional Shares”). The Firm Shares and the Additional Shares are hereinafter collectively sometimes referred to as the “Shares.” The Shares are described in the Prospectus which is referred to below.
RECITALSCollaboration and License Agreement • July 22nd, 2002 • Hyseq Inc • In vitro & in vivo diagnostic substances • California
Contract Type FiledJuly 22nd, 2002 Company Industry Jurisdiction
PLACEMENT AGENCY AGREEMENT January 21, 2014Placement Agency Agreement • February 4th, 2014 • ARCA Biopharma, Inc. • In vitro & in vivo diagnostic substances • New York
Contract Type FiledFebruary 4th, 2014 Company Industry JurisdictionIntroduction. Subject to the terms and conditions herein (this “Agreement”), ARCA biopharma, Inc., a Delaware corporation (the “Company”), proposes to offer and sell registered securities of the Company, including, but not limited to, shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), and registered warrants to purchase Common Stock (the “Warrants” and, together with the Shares, and the Common Stock underlying the Warrants, the “Securities”) directly to various investors (each, an “Investor” and, collectively, the “Investors”) through Dawson James Securities, Inc., as placement agent (“Dawson” or the “Placement Agent”).
AMGEN INC. AND HYSEQ, INC.License Agreement • July 22nd, 2002 • Hyseq Inc • In vitro & in vivo diagnostic substances • California
Contract Type FiledJuly 22nd, 2002 Company Industry Jurisdiction
Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934,...Joint Filing Agreement • February 14th, 2007 • Nuvelo Inc • In vitro & in vivo diagnostic substances
Contract Type FiledFebruary 14th, 2007 Company IndustryThe undersigned hereby agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and that all subsequent amendments to this statement on Schedule 13G may be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements.
ContractARCA Biopharma, Inc. • March 27th, 2009 • In vitro & in vivo diagnostic substances • Delaware
Company FiledMarch 27th, 2009 Industry JurisdictionTHIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AND PURSUANT TO THE PROVISIONS OF ARTICLE 5 BELOW, MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND APPLICABLE STATE SECURITIES LAW OR, IN THE OPINION OF LEGAL COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER OF THESE SECURITIES, SUCH OFFER, SALE OR TRANSFER, PLEDGE OR HYPOTHECATION IS EXEMPT FROM REGISTRATION.
EXHIBIT 10.28 COLLABORATION AGREEMENT BY AND BETWEENLicense Agreement • May 15th, 2002 • Hyseq Inc • In vitro & in vivo diagnostic substances • California
Contract Type FiledMay 15th, 2002 Company Industry Jurisdiction